- Home
- PYN vs FEMY Comparison
PYN vs FEMY Comparison
Compare PYN & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- FEMY
- Stock Information
- Founded
- PYN 2002
- FEMY 2004
- Country
- PYN United States
- FEMY United States
- Employees
- PYN N/A
- FEMY N/A
- Industry
- PYN Investment Managers
- FEMY Medical/Dental Instruments
- Sector
- PYN Finance
- FEMY Health Care
- Exchange
- PYN Nasdaq
- FEMY Nasdaq
- Market Cap
- PYN 30.1M
- FEMY 29.9M
- IPO Year
- PYN N/A
- FEMY 2021
- Fundamental
- Price
- PYN $5.09
- FEMY $0.83
- Analyst Decision
- PYN
- FEMY Strong Buy
- Analyst Count
- PYN 0
- FEMY 3
- Target Price
- PYN N/A
- FEMY $8.67
- AVG Volume (30 Days)
- PYN 19.9K
- FEMY 151.8K
- Earning Date
- PYN 01-01-0001
- FEMY 08-07-2025
- Dividend Yield
- PYN 5.07%
- FEMY N/A
- EPS Growth
- PYN N/A
- FEMY N/A
- EPS
- PYN N/A
- FEMY N/A
- Revenue
- PYN N/A
- FEMY $1,699,232.00
- Revenue This Year
- PYN N/A
- FEMY $283.83
- Revenue Next Year
- PYN N/A
- FEMY $161.03
- P/E Ratio
- PYN N/A
- FEMY N/A
- Revenue Growth
- PYN N/A
- FEMY 61.97
- 52 Week Low
- PYN $4.84
- FEMY $0.69
- 52 Week High
- PYN $6.60
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- PYN 35.88
- FEMY 36.62
- Support Level
- PYN $5.05
- FEMY $0.91
- Resistance Level
- PYN $5.12
- FEMY $0.93
- Average True Range (ATR)
- PYN 0.06
- FEMY 0.04
- MACD
- PYN -0.01
- FEMY -0.01
- Stochastic Oscillator
- PYN 14.81
- FEMY 0.00
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.